**Correction to:** *British Journal of Cancer* (2014) **110**, 133--145; doi:[10.1038/bjc.2013.673](/doifinder/10.1038/bjc.2013.673)

The authors have become aware of an error in [Figure 1](#fig1){ref-type="fig"} in which one of the images (panel E, *α*-G-CSFR) was inadvertently duplicated (in panel H, *α*-pSTAT3). The corrected [Figure 1](#fig1){ref-type="fig"} is reproduced below.

![**Expression of G-CSF/G-CSFR in ovarian cancer.** (**A**, **B**) Expression of G-CSF/G-CSFR in primary ovarian cancers. RNA derived from the indicated patient samples were analysed with primers specific for *G-CSF*, *G-CSFR*, *IL-6*, *IL-6R* and *β-ACTIN* as a control. This analysis used either semi-quantitative RT--PCR with expression of *G-CSF*, *G-CSFR*, *IL-6* and *IL-6R* scored on a five-point scale on the indicated tumour samples (**A**), or by qRT--PCR for *G-CSFR* relative to *β-ACTIN* on Grade 3 tumour samples (**B**). (**C**--**J**) Detection of G-CSFR and phospho-STAT3 in ovarian cancer. Immunohistochemical staining of normal ovary (**C**, **F**), benign tumour (**D**, **G**) or Grade 3 (**E**, **H**) tumour samples with anti-G-CSFR (**C**--**E**) or anti-pSTAT3 (**F**--**H**) as indicated. Arrows indicate scattered epithelial staining with both antibodies in Grade 3 tumours, and arrowheads indicate vessel-associated staining. Immunohistochemical staining with anti-G-CSFR or anti-pSTAT3 was scored on a scale of 0--5, and represented as a scatter-plot for normal ovary, benign and pooled tumour groups, with the level of statistical significance indicated (**I**, **J**, \**P*\<0.05, NS: not significant). (**K**--**M**) Expression of G-CSF/G-CSFR in a panel of ovarian cancer cell lines. Cells were analysed by RT--PCR for expression of the indicated genes (**K**), subjected to FACS analysis using anti-G-CSFR-PE (red line) or an isotype control (black line) (**L**), or conditioned media obtained and analysed for G-CSF by ELISA (**M**).](bjc2015389f1){#fig1}
